P/E at 35.19 vs Industry's 37.56: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount to Industry P/E

The current P/E of 35.19 for Sun Pharmaceutical Industries Ltd represents a modest discount of approximately 6.4% relative to the sector average of 37.56. This suggests that the market is pricing the stock with a slightly more conservative outlook compared to its peers. Given the sector’s broad valuation range, this premium or discount can reflect investor sentiment on growth prospects, risk factors, or recent earnings trends. The stock’s large-cap status, with a market capitalisation of ₹4,42,773.28 crores, further anchors its valuation within the upper echelons of the Pharmaceuticals & Biotechnology sector.

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple timeframes reveals a mixed performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 13.35% gain, significantly outperforming the Sensex’s 9.19% loss during the same period. This outperformance extends to longer horizons as well, with three-year and five-year returns of 64.17% and 139.76% respectively, dwarfing the Sensex’s 11.63% and 22.73% gains. However, the short-term picture is less encouraging: the stock has declined by 0.90% over the last three months, while the Sensex fell 4.41%. This relative resilience in a down market contrasts with the stock’s negative one-month return of 3.74%, which is slightly better than the Sensex’s 5.09% drop but still indicative of recent weakness. The 1-week and 1-day performances show minor gains and losses respectively, with the stock outperforming the sector by 0.56% today despite a 0.41% decline.

The 5% surge partially reverses a 6.45% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Mixed Technical Signals

The technical setup for Sun Pharmaceutical Industries Ltd is characterised by a nuanced moving average (MA) configuration. The stock price currently sits above its 5-day and 200-day moving averages but remains below the 20-day, 50-day, and 100-day MAs. This pattern suggests a short-term recovery attempt within a broader intermediate-term consolidation or downtrend. The position above the 200-day MA is a positive long-term signal, indicating that the stock has not broken down into a sustained bear phase. However, the failure to clear the mid-term MAs points to resistance and potential volatility ahead. This technical divergence aligns with the recent performance data, where short-term weakness contrasts with longer-term strength.

Sector Performance Context

The Pharmaceuticals & Biotechnology sector has seen mixed results in its recent earnings season. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution reflects a sector grappling with uneven growth drivers and regulatory challenges. Within this context, Sun Pharmaceutical Industries Ltd’s relative stability and valuation discount may be interpreted as a cautious market stance amid sector-wide uncertainty. The stock’s ability to outperform the Sensex over multiple timeframes despite these headwinds is notable and raises questions about its resilience compared to peers — how does this influence the current rating?

Rating Reassessment and Historical Context

Previously rated Buy by MarketsMOJO, Sun Pharmaceutical Industries Ltd had its rating updated on 03 Sep 2026. The reassessment reflects the evolving valuation-performance dynamics and technical signals outlined above. While the stock’s Mojo Score stands at 67.0, the rating change suggests a more cautious stance given the recent short-term underperformance and mixed technical indicators. The data-driven approach behind this reassessment emphasises the importance of balancing valuation premiums with momentum and sector trends — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Collective Data Insights

Bringing together valuation, performance, technical, and sector data paints a picture of a stock that remains fundamentally sound but faces short-term headwinds. The modest discount to industry P/E suggests the market is not overly optimistic, yet the long-term returns and large-cap stature provide a solid foundation. The mixed moving average configuration signals a tentative recovery rather than a confirmed uptrend, while the sector’s uneven earnings results add a layer of caution. The rating update from Buy to Hold reflects these complexities and underscores the need for investors to weigh recent momentum against historical strength carefully.

Given this multifaceted scenario, what is the current rating for Sun Pharmaceutical Industries Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →